凯因科技2025年度归母净利润2963.12万元 同比下降79.19%

Core Viewpoint - The company reported a total operating revenue of 1.321 billion yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.35%. However, the net profit attributable to the parent company was 29.6312 million yuan, showing a significant decline of 79.19% compared to the previous year due to substantial asset impairment provisions [1]. Financial Performance - Total operating revenue reached 1.321 billion yuan, marking a 7.35% increase year-on-year [1]. - Net profit attributable to the parent company was 29.6312 million yuan, which represents a 79.19% decrease year-on-year [1]. Reasons for Performance Changes - The primary reason for the performance decline was the company's decision to make a large asset impairment provision. This was influenced by the latest review recommendations from the National Medical Products Administration [1]. - The company voluntarily withdrew the drug registration application for the interferon α-2 injection (new hepatitis B indication), leading to a full impairment provision for the remaining development expenses of this project [1].